Literature DB >> 7002680

Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps.

A Pietri, A L Ehle, P Raskin.   

Abstract

Near normal glucoregulation was maintained in 10 patients with insulin-dependent (type I) diabetes mellitus for 6 wk with preprogrammed continuous subcutaneous insulin infusion using a portable battery-powered infusion pump (CSII). This form of therapy resulted in a statistically significant increase in motor nerve conduction velocity in the median and peroneal nerves compared with baseline values. There was no significant change in the motor nerve conduction velocity in the ulnar nerve or in the sensory nerve conduction studies. No changes occurred in five additional patients studied in similar fashion while on a conventional insulin regimen. These results suggest that the prevention of sustained hyperglycemia with CSII could theoretically result in the prevention of diabetic neuropathy. However, only long-term studies of CSII will provide the information necessary to determine the clinical relevance of the findings.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002680     DOI: 10.2337/diab.29.8.668

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  32 in total

1.  Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy.

Authors:  L Wuarin-Bierman; G R Zahnd; F Kaufmann; L Burcklen; J Adler
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

2.  A comparison of nerve conduction velocities and current perception thresholds as correlates of clinical severity of diabetic sensory neuropathy.

Authors:  M S Rendell; J J Katims; R Richter; F Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

3.  A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.

Authors:  A J Boulton; S Levin; J Comstock
Journal:  Diabetologia       Date:  1990-07       Impact factor: 10.122

4.  Continuous subcutaneous insulin infusion: a long-term study.

Authors:  A Lombardo; S Scavino; G Scornavacca; G Oliva; C Sipione; R Cacciola; L Motta
Journal:  Acta Diabetol Lat       Date:  1986 Jan-Mar

Review 5.  Diabetic control and microvascular complications: the near-normoglycaemic experience.

Authors:  K F Hanssen; K Dahl-Jørgensen; T Lauritzen; B Feldt-Rasmussen; O Brinchmann-Hansen; T Deckert
Journal:  Diabetologia       Date:  1986-10       Impact factor: 10.122

6.  Near normoglycaemia improved nerve conduction and vibration sensation in diabetic neuropathy.

Authors:  F J Service; R A Rizza; J R Daube; P C O'Brien; P J Dyck
Journal:  Diabetologia       Date:  1985-10       Impact factor: 10.122

7.  Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.

Authors:  I G Lewin; I A O'Brien; M H Morgan; R J Corrall
Journal:  Diabetologia       Date:  1984-06       Impact factor: 10.122

8.  Influence of continuous subcutaneous insulin infusion (CSII) treatment on diabetic somatic and autonomic neuropathy.

Authors:  D Fedele; P Negrin; C Cardone; F Bellavere; M Ferri; G Briani; R Nosadini; G Crepaldi
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

9.  Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion.

Authors:  F W Bertelsmann; J J Heimans; J C Van Rooy; H F Dankmeijer; S L Visser; E A Van der Veen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

Review 10.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.